Company intelligence / Profile preview

Hy

Los Angeles, California, United States

Ownership: Private
Development stage: Other

Overview

Hy is a consumer biotechnology company focused on developing science-backed longevity and metabolic health solutions. The company specializes in the commercialization of high-purity Nicotinamide Adenine Dinucleotide (NAD+) precursors and related supplements designed to support cellular energy and healthy aging. Hy differentiates itself through a focus on pharmaceutical-grade quality and rigorous testing of its consumer-facing health products. Their business model combines direct-to-consumer sales with ongoing research into the efficacy of NAD+ boosting for various age-related conditions.

Therapeutic areas: NeurologyOtherMetabolic Disorders
Modalities: Small moleculeNutraceutical
Industry: Food & Nutrition

Beyond the preview

Go deeper on Hy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hy.

Explore the full profile